What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma’s nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.
J&J ends JNJ-5939 trial early in atopic dermatitis after missing efficacy mark
Johnson & Johnson (J&J) announced that its investigational candidate JNJ-95475939 (JNJ-5939) failed to meet prespecified efficacy criteria in the DUPLEX-AD Phase 2b trial for moderate to severe atopic dermatitis. Following an interim analysis, the study was terminated early. Despite showing a favorable tolerability profile, the molecule did not demonstrate sufficient clinical efficacy to warrant continuation. […]